Viral vector manufacturing sits at the leading edge of modern medicine. So, the potential of utilizing genetically engineered viruses as vehicles for delivering genetic material has opened therapeutic doors that were closed a generation ago. Viral vector manufacturing standards are stringent, and the science behind it is complex, whether for gene therapies, vaccine platforms, or cell therapy applications.

However, in that complexity, analytical testing cannot be a mere sidekick. It plays a crucial role in the various stages of the production process, ranging from initial production development to the final product release for commercial use. Even the best and most advanced mycoplasma viral vector manufacturing process is flying ‘blind’ if powerful and properly designed analytical frameworks do not underpin it. Analytical testing provides the data that’s used to make decisions at each stage of development and production, and they’re only as good as what comes from it.

The processes of Viral Vector Manufacturing

To appreciate the demand for viral vector manufacturing, it is important to first learn why viral vector manufacturing is so challenging.

Viral vectors are manufactured viruses containing the genetic material to be inserted into the host cell system, which replicates the vector along the lines of instructions given. Examples of vectors include adeno-associated viruses, lentiviral vectors, and adenoviral vectors, with different biological properties and production requirements. The manufacturing process consists of three steps: (1) upstream cell culture, (2) downstream purification and concentration, and (3) the final formulation step for the end use of the product.

The product is constantly evolving at each step. Cells are living in a biological environment that is inherently variable and are growing, expressing, and producing material. Purification steps remove impurities, but not the active product. Every transition is prone to adding variability or allowing deterioration of product quality if there is no tight control and understanding of the transition process. That understanding is entirely reliant on the cell therapy analytical testing applied throughout, which depends almost entirely on the quality and depth of the analytical testing.

Potency and Identity Testing

Once you know you have created a viral vector, you have to create a specific one. Making a viral vector is just the beginning; it’s time to make a specific one. To know it is the right vector, has the right genetic payload, and is capable of doing what it’s supposed to do when it arrives at its desired tissue is something else, and much more challenging.

Potency testing takes the question head-on. It tests the biological activity of the vector to verify that the product is infectable in the cell type of interest and is able to successfully deliver its genetic payload. It’s not a straightforward measurement. Potency assays need to be carefully designed, validated, and consistently performed to yield real product potency data and not an artefact of the test system.

Along with potency testing, identity testing is performed to ensure that the vector of a particular batch is the one that is described in the manufacturing record. All sequence verification, tropism confirmation, and genetic integrity assessments are in this category. If a vector is going to be used in a clinical setting, it is essential that the ability to demonstrate that the vector is properly designed and has not been damaged during construction.

The characterisation of Purity and Impurity

Viral vectors are produced in a biological process that yields a complex mixture of material, only part of which is the desired viral vectors. There are also a variety of impurities, such as empty capsids, residual host cell proteins, residual DNA from the host cell line, process-related chemicals, and aggregated particles, that should be characterised, quantified, and controlled.

Purity analytical testing is a multi-dimensional challenge. There is no single test that would give a complete impurity profile of a viral vector preparation. Several alternate techniques are used; however, all address different types of possible contaminants. There are techniques such as analytical ultracentrifugation, mass spectrometry, enzyme-linked immunosorbent assays, and next-generation sequencing, which each provide a different aspect of the purity story.

The importance of stability and its basics in product development

If the viral vector is not stable after manufacture, but breaks down during storage or transport, it will not be very useful in a clinical setting. Stability testing quantifies the changes that occur in the product over time with different storage conditions, providing the manufacturer with the information necessary to set up storage conditions, reasonable shelf-life specifications, and formulate strategies that will help the product to remain stable over time.

Designing stability programmes for viral vectors is challenging, as some of the attributes contributing to product quality may not be the most critical attributes most sensitive to degradation. The rate at which potency changes, the rate at which particle concentration changes, the rate at which aggregation state changes, and the ratio of functional to non-functional particles can all change at different rates under different conditions. Only one/two attribute stability testing programmes could fail to detect significant changes that would impact clinical performance or patient safety.

Supporting the scaling up and development of processes

Analytical testing is not just used as a quality control tool for the finished product. It also becomes important when developing a process, when manufacturing conditions are being defined and optimised before large-scale manufacture.

To be able to accurately and reproducibly measure the yield and quality of vectors is necessary to understand how changing the upstream cell culture conditions will affect the vector. To assess the efficacy of various purification processes downstream, a suite of tests to measure very small differences in purity and potency between process variants must be available. Analytical methods must be sensitive enough to show that there are no significant differences between material produced in the laboratory and manufacturing that would have a clinical impact if it is shown that the process can be scaled up from the laboratory to manufacturing.

Conclusion

Analytical testing in the production of viral vectors is not conducted in a vacuum, but rather alongside the regulatory processes that are in place to ensure the availability of these products for the benefit of patients. The regulatory agencies expect manufacturers to prove their analytical methods are fit for the purpose; to validate them to an appropriate standard; and to support the specifications set for product release with a scientifically valid reason and clinical relevance.

Xellera Therapeutics focuses on strong testing and clean processes. You can do the same by staying aware and careful at all times. Sign up for more information.